Holen Sie sich die Stockscreener-App
2.02
0.98%
-0.02
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan
MAIA Biotech Secures FDA Rare Pediatric Disease Status for Novel Brain Cancer Drug, Eyes $100M Voucher - StockTitan
Stan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock - MarketBeat
Maia Biotechnology director Stan Smith acquires $46,800 in stock - Investing.com India
Maia Biotechnology director Stan Smith acquires $46,800 in stock By Investing.com - Investing.com South Africa
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock - Investing.com
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock By Investing.com - Investing.com UK
MAIA Biotechnology, Inc. announced that it expects to receive $0.949785 million in funding - Marketscreener.com
MAIA Biotechnology announces $950,000 private placement - MSN
MAIA Biotechnology Secures $950K Private Placement to Advance THIO Clinical Trials - StockTitan
MAIA Biotech expands phase 2 trial for lung cancer treatment By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - XM
MAIA Biotech expands phase 2 trial for lung cancer treatment - Investing.com
Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings - Defense World
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer - Cancer Network
MAIA Biotechnology Inc (MAIA): A New Perspective - Stocks Register
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
MAIAMAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - BioSpace
MAIA Director Backs Cancer Drug Developer with $225,900 Stock Purchase, Shows Insider Confidence - StockTitan
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance
MAIA Biotech's NSCLC Treatment Shows 83% Survival Boost Over Standard Care in Trial - StockTitan
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Canada
Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock - MarketBeat
Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechno - GuruFocus.com
Director Ramiro Guerrero Acquires 88,534 Shares of MAIA Biotechn - GuruFocus.com
Maia Biotechnology director Steven Chaouki buys $55,553 in shares By Investing.com - Investing.com Australia
Maia Biotechnology director Steven Chaouki buys $55,553 in shares - Investing.com
Maia Biotechnology director Luput acquires shares worth $55,553 By Investing.com - Investing.com Nigeria
Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com
Cosmo Metals Secures $500,000 for Strategic Expansion - MSN
Antipa Minerals Expands Share Offering on ASX - MSN
WAM Alternative Assets Expands ASX Securities Offering - MSN
Argent BioPharma Issues New Shares Amidst Strategic Growth - MSN
MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4%Here's What Happened - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% – Time to Sell? - Defense World
Alterity Therapeutics Prepares for 2024 Annual General Meeting - MSN
Li Bang International announces pricing of initial public offering - MSN
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - BioSpace
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 1.1% - MarketBeat
BioAge, BKV shares end their first trading day flat after earlier gains - MSN
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO - MSN
Healthcare Stock Performance - Yahoo Finance
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE) - Defense World
Promising signs for MAIA’s telomere-targeting treatment - The Pharma Letter
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8% - Defense World
THIO Combo Yields Survival Benefit in Advanced NSCLC - AJMC.com Managed Markets Network
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CAE - PR Newswire
Summit Therapeutics jumps 4%, raises $235M - MSN
MAIA Biotechnology - The Pharma Letter
MAIA Biotechnology Reports Promising Interim Results in Lung Cancer Treatment Study - Vancity Buzz
MAIA Biotechnology Inc’s latest rating changes from various analysts - Knox Daily
MAIA reports survival benefit in advanced lung cancer trial - Investing.com
2.88%
2.65%
Kapitalisierung:
|
Volumen (24h):